Fiona M. Campbell

发表

Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients

John M.S. Bartlett, J. Bartlett, K. Nielsen, 2007, Clinical Cancer Research.

Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience

Margaret Grant, D. Rea, F. Campbell, 2009, Histopathology.

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH

J. Bartlett, K. Nielsen, T. Kirkegaard, 2010, Histopathology.

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

John M S Bartlett, Hein Putter, Cornelis J H van de Velde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.

J. Bartlett, B. Jasani, F. Campbell, 2012, American journal of clinical pathology.

Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients

H. Putter, P. Kuppen, J. Bartlett, 2011, Breast Cancer Research and Treatment.

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.

I. Ellis, B. Jasani, A. O'Grady, 2009, American journal of clinical pathology.

Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Hans Christian Pedersen, D. Ross, B. Ring, 2010, Breast Cancer Research.

Explorer Mammostrat ( R ) as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

D. Ross, B. Ring, G. Kerr, 2010 .

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

C. Caldas, E. Provenzano, H. Earl, 2010, The Lancet. Oncology.

Mammostrat® as a tool to stratify patients at risk of recurrence during endocrine therapy.

D. Ross, B. Ring, G. Kerr, 2009 .

A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech™ HER2 FISH probe.

I. Ellis, A. O'Grady, E. Kay, 2009 .

HER 2 Gene Amplification in Breast Cancer

J. Bartlett, B. Jasani, F. Campbell, 2012 .

In Situ Hybridisation For Pharmacodiagnostic Testing

J. Bartlett, F. Campbell, Fiona M. Campbell, 2010, Molecular Diagnostics.

A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.

N. Collins, B. Jasani, F. Campbell, 2011, American journal of clinical pathology.

A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH

I. Ellis, J. Bartlett, F. Campbell, 2010, Histopathology.

Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.

I. Ellis, B. Jasani, F. Campbell, 2009, American journal of clinical pathology.

Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?

J. Bartlett, E. Mallon, F. Campbell, 2008, American journal of clinical pathology.

Histological grading of invasive breast carcinoma – a simplification of existing methods in a large conservation series with long‐term follow‐up

John M S Bartlett, G. Kerr, U. Chetty, 2009, Histopathology.

The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.

H. Putter, R. Paridaens, C. Seynaeve, 2009 .

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

Alastair I. Bartlett, D. Rea, C. Seynaeve, 2011, American journal of clinical pathology.

CD4+ and CD8+ T‐lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia

S. Vowler, K. Grigor, J. Bartlett, 2011, BJU international.

Fluorescent In Situ Hybridization

J. Bartlett, Fiona M. Campbell, 2007 .

Is the biology of breast cancer changing? A study of hormone receptor status and grade of breast cancers 1984-1986 and 1996-97.

E. Mallon, J. Edwards, L. Mcglynn, 2009 .

External Quality Assurance Schemes: The Impact of Participation in the UK Versus Rest of the World: 5 Year Data from the UK National External Quality Assurance Scheme.

B. Jasani, A. O'Grady, E. Kay, 2009 .

Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial

C. Caldas, E. Provenzano, H. Earl, 2009 .

The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

J. Bartlett, J. Dixon, D. Faratian, 2011, Breast Cancer Research and Treatment.

Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience

D. Rea, D. Faratian, T. Robson, 2009, Histopathology.

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.

Alastair I. Bartlett, D. Rea, C. Seynaeve, 2011, American journal of clinical pathology.

Frequent amplifications and deletions of G1/S-phase transition genes, CCND1 and MYC in early breast cancers: a potential role in G1/S escape.

J. Bartlett, K. Nielsen, T. Kirkegaard, 2009, Cancer biomarkers : section A of Disease markers.